Looking at the Effect of Reducing Steroid Use in Myasthenia Gravis Patients
Recruiting · Phase 4 · Generalized Myasthenia Gravis and related conditions · Illinois, New Jersey, North Carolina and Tennessee
About this trial
This study looks at how a specific plan to lower the use of oral corticosteroids can help adults with generalized myasthenia gravis who are being treated with ravulizumab. The study aims to see if this tapering schedule is effective and safe for participants. Generalized myasthenia gravis is a condition that affects muscle strength and control.
This study is identified as NCT07221838. It is a Phase 4 trial, which means it is looking at how well the treatment works and its safety. The study is regulated by the FDA and aims to enroll about 75 participants.
Who can join
Adults aged 18 and older, both men and women, can join this study. Participants must have a diagnosis of generalized myasthenia gravis and be receiving treatment with ravulizumab. They should have been taking a certain amount of oral corticosteroids for at least four weeks before joining. People currently in another clinical trial or with specific medical histories cannot join. The trial team will confirm eligibility.
Conditions
Generalized Myasthenia Gravis, gMG
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will follow a schedule to gradually lower their oral corticosteroid dose. They will also continue receiving intravenous ravulizumab as part of their treatment. The study does not involve comparing different groups; all participants will follow the same tapering plan. The goal is to see how many participants can successfully reduce or stop using corticosteroids without worsening their condition.
Where
This trial is enrolling at 5 locations. Recruiting sites are listed first.